Skip to main content

Advertisement

Log in

Up-front F18-FDG PET/CT in suspected salivary gland carcinoma

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

To investigate whether a 18F-FDG PET/CT (PET/CT)-based diagnostic strategy adds decisive new information compared to conventional imaging in the evaluation of salivary gland tumours and the detection of cervical lymph node metastases, distant metastases, and synchronous cancer in patients with salivary gland carcinoma.

Methods

The study was a blinded prospective cohort study. Data were collected consecutively through almost 3 years. All patients underwent conventional imaging—magnetic resonance imaging (MRI) and chest X-ray (CXR)—in addition to PET/CT prior to surgery. Final diagnosis was obtained by histopathology. MRI/CXR and PET/CT were interpreted separately by experienced radiologists and nuclear medicine physicians. Interpretation included evaluation of tumour site, cervical lymph node metastases, distant metastases, and synchronous cancer.

Results

Ninety-one patients were included in the study. Thirty-three patients had primary salivary gland carcinoma and eight had cervical lymph node metastases. With PET/CT, the sensitivity was 92% and specificity 29% regarding tumour site. With MRI/CXR, the sensitivity and specificity were 90% and 26%, respectively. Regarding cervical lymph node metastases in patients with salivary gland carcinoma, the sensitivity with PET/CT was 100% and with MRI/CXR 50%. PET/CT diagnosed distant metastases in five patients, while MRI/CXR detected these in two patients. Finally, PET/CT diagnosed two synchronous cancers, whereas MRI/CXR did not detect any synchronous cancers.

Conclusions

Compared with MRI/CXR PET/CT did not improve discrimination of benign from malignant salivary gland lesions. However, PET/CT may be advantageous in primary staging and in the detection of distant metastases and synchronous cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Pinkston JA, Cole P. Incidence rates of salivary gland tumors: results from a population-based study. Otolaryngol Head Neck Surg. 1999;120(6):834–40.

    Article  CAS  PubMed  Google Scholar 

  2. Spiro RH. The management of salivary neoplasms: an overview. Auris Nasus Larynx. 1985;12(Suppl 2):S122–7.

    Article  PubMed  Google Scholar 

  3. Eveson JW, Cawson RA. Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol. 1985;146(1):51–8.

    Article  CAS  PubMed  Google Scholar 

  4. Bjorndal K, et al. Salivary gland carcinoma in Denmark 1990–2005: a national study of incidence, site and histology Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol. 2011;47(7):677–82.

    Article  PubMed  Google Scholar 

  5. Barnes L, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours. Lyon: IARC; 2005.

    Google Scholar 

  6. Bjorndal K, et al. Salivary gland carcinoma in Denmark 1990-2005: outcome and prognostic factors. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol. 2012;48(2):179–85.

    Article  PubMed  Google Scholar 

  7. Bell RB, et al. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg. 2005;63(7):917–28.

    Article  PubMed  Google Scholar 

  8. Jegadeesh N, et al. Outcomes and prognostic factors in modern era management of major salivary gland cancer. Oral Oncol. 2015;51(8):770–7.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ali S, et al. Postoperative nomograms predictive of survival after surgical management of malignant tumors of the major salivary glands. Ann Surg Oncol. 2014;21(2):637–42.

    Article  PubMed  Google Scholar 

  10. DAHANCA, Nationale retningslinier for udredning og behandling af spytkirtelkræft i Danmark. 2010, Ver 1.1.

  11. McGuirt WF, et al. Preoperative identification of benign versus malignant parotid masses: a comparative study including positron emission tomography. Laryngoscope. 1995;105(6):579–84.

    Article  CAS  PubMed  Google Scholar 

  12. Okamura T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of parotid mass lesions. Acta Otolaryngol Suppl. 1998;538:209–13.

    CAS  PubMed  Google Scholar 

  13. Ozawa N, et al. Retrospective review: usefulness of a number of imaging modalities including CT, MRI, technetium-99 m pertechnetate scintigraphy, gallium-67 scintigraphy and F-18-FDG PET in the differentiation of benign from malignant parotid masses. Radiat Med. 2006;24(1):41–9.

    Article  PubMed  Google Scholar 

  14. Rassekh CH, et al. Positron emission tomography in Warthin’s tumor mimicking malignancy impacts the evaluation of head and neck patients. Am J Otolaryngol. 2015;36(2):259–63.

    Article  PubMed  Google Scholar 

  15. Wang HC, et al. Efficacy of conventional whole-body (1)(8)F-FDG PET/CT in the incidental findings of parotid masses. Ann Nucl Med. 2010;24(8):571–7.

    Article  PubMed  Google Scholar 

  16. Nakamoto Y, et al. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology. 2005;234(3):879–85.

    Article  PubMed  Google Scholar 

  17. Hadiprodjo D, et al. Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters. AJR Am J Roentgenol. 2012;198(2):W185–90.

    Article  PubMed  Google Scholar 

  18. Bertagna F, et al. Diagnostic role of (18)F-FDG-PET or PET/CT in salivary gland tumors: a systematic review. Rev Esp Med Nucl Imagen Mol. 2015;34(5):295–302.

    CAS  PubMed  Google Scholar 

  19. Jeong HS, et al. Role of 18F-FDG PET/CT in management of high-grade salivary gland malignancies. J Nucl Med. 2007;48(8):1237–44.

    Article  PubMed  Google Scholar 

  20. Otsuka H, et al. The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med. 2005;19(8):691–4.

    Article  PubMed  Google Scholar 

  21. Razfar A, et al. Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope. 2010;120(4):734–8.

    Article  PubMed  Google Scholar 

  22. Roh JL, et al. Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med. 2007;48(2):240–6.

    PubMed  Google Scholar 

  23. Rubello D, et al. Does 18F-FDG PET/CT play a role in the differential diagnosis of parotid masses. Panminerva Med. 2005;47(3):187–9.

    CAS  PubMed  Google Scholar 

  24. Cermik TF, et al. FDG PET in detecting primary and recurrent malignant salivary gland tumors. Clin Nucl Med. 2007;32(4):286–91.

    Article  PubMed  Google Scholar 

  25. Rohde M, et al. Head-to-head comparison of chest x-ray/head and neck MRI, chest CT/head and neck MRI, and 18F-FDG-PET/CT for detection of distant metastases and synchronous cancer in oral, pharyngeal, and laryngeal Cancer. J Nucl Med. 2017;58(12):1919–24.

    Article  CAS  PubMed  Google Scholar 

  26. Rohde M, et al. A PET/CT-based strategy is a stronger predictor of survival than a standard imaging strategy in patients with head and neck squamous cell carcinoma. J Nucl Med. 2018;59(4):575–81.

    Article  CAS  PubMed  Google Scholar 

  27. Rohde M, et al. Up-front PET/CT changes treatment intent in patients with head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2017;45(4):613–21.

    Article  CAS  PubMed  Google Scholar 

  28. Roennegaard AB, et al. The Danish Head and Neck Cancer fast-track program: a tertiary cancer centre experience. Eur J Cancer. 2017;90:133–9.

    Article  PubMed  Google Scholar 

  29. Rohde M, et al. 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis. Eur J Cancer. 2014;50(13):2271–9.

    Article  PubMed  Google Scholar 

  30. Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4(1):5.

    PubMed  Google Scholar 

  31. Lee YY, et al. Imaging of salivary gland tumours. Eur J Radiol. 2008;66(3):419–36.

    Article  CAS  PubMed  Google Scholar 

  32. Burke CJ, Thomas RH, Howlett D. Imaging the major salivary glands. Br J Oral Maxillofac Surg. 2011;49(4):261–9.

    Article  CAS  PubMed  Google Scholar 

  33. Kwee TC, et al. A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging. 2011;38(6):1158–70.

    Article  PubMed  Google Scholar 

  34. Kendi AT, et al. Is there a role for PET/CT parameters to characterize benign, malignant, and metastatic parotid tumors? AJR Am J Roentgenol. 2016;207(3):635–40.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Keyes JW Jr, et al. Salivary gland tumors: pretherapy evaluation with PET. Radiology. 1994;192(1):99–102.

    Article  PubMed  Google Scholar 

  36. Uchida Y, et al. Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors. Clin Nucl Med. 2005;30(3):170–6.

    Article  PubMed  Google Scholar 

  37. Toriihara A, et al. Can dual-time-point 18F-FDG PET/CT differentiate malignant salivary gland tumors from benign tumors? AJR Am J Roentgenol. 2013;201(3):639–44.

    Article  PubMed  Google Scholar 

  38. Treglia G, et al. Prevalence and risk of malignancy of focal incidental uptake detected by fluorine-18-fluorodeoxyglucose positron emission tomography in the parotid gland: a meta-analysis. Eur Arch Otorhinolaryngol. 2015;272(12):3617–26.

    Article  PubMed  Google Scholar 

  39. Horiuchi M, et al. Four cases of Warthin’s tumor of the parotid gland detected with FDG PET. Ann Nucl Med. 1998;12(1):47–50.

    Article  CAS  PubMed  Google Scholar 

  40. Horiuchi C, et al. Correlation between FDG-PET findings and GLUT1 expression in salivary gland pleomorphic adenomas. Ann Nucl Med. 2008;22(8):693–8.

    Article  CAS  PubMed  Google Scholar 

  41. Kim MJ, et al. Utility of 18F-FDG PET/CT for detecting neck metastasis in patients with salivary gland carcinomas: preoperative planning for necessity and extent of neck dissection. Ann Surg Oncol. 2013;20(3):899–905.

    Article  PubMed  Google Scholar 

  42. Kim JY, et al. Diagnostic value of neck node status using 18F-FDG PET for salivary duct carcinoma of the major salivary glands. J Nucl Med. 2012;53(6):881–6.

    Article  PubMed  Google Scholar 

  43. Bradley PJ. Distant metastases from salivary glands cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63(4):233–42.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marie Westergaard-Nielsen.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare. The research has been supported as PhD thesis by University of Southern Denmark.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Westergaard-Nielsen, M., Rohde, M., Godballe, C. et al. Up-front F18-FDG PET/CT in suspected salivary gland carcinoma. Ann Nucl Med 33, 554–563 (2019). https://doi.org/10.1007/s12149-019-01362-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-019-01362-9

Keywords

Navigation